Abilita Bio, Inc is an innovation-driven biotechnology company based in San Diego, California. They specialize in the discovery and development of drugs targeting challenging membrane proteins, such as G Protein-Coupled Receptors (GPCRs) and ion channels, to address the pressing need for new, effective, and safer treatments for diseases like cancer, diabetes, inflammation, and neurology.
With a focus on enabling drug discovery, Abilita Bio has developed a powerful and fully integrated discovery platform that harnesses cutting-edge technologies and methods. Their proprietary technology, which leverages directed evolution, identifies enhanced target variants called EMPs (Enabled Membrane Proteins) that can overcome the inherent difficulties of working with membrane proteins while maintaining the relevant protein structure. This platform enables antibody discovery, structure-based drug discovery, and protein-based small molecule discovery, providing a rich pipeline of unique assets for the development of novel therapeutics.
Generated from the website